Although this is a theoretical conclusion, this might play a crucial role in explaining the reason why adding DFMO as maintenance therapy in pediatric neuroblastoma could successfully increase EFS by almost 30% from an average of 55% to around 85%, thereby making ODC a very important target in the management of cancers with elevated polyamine metabolism and Myc mutations - which is seen in neuroblastoma. This evidence concerns the gene MYC and neuroblastoma.